We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit

TelesisBio logo.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Telesis Bio Inc., announced the first commercial shipment of its BioXp® Select DNA Cloning kit. The BioXp® Select DNA Cloning kit enables on-demand and automated assembly of DNA fragments via Gibson Assembly® or Golden Gate assembly cloning methods beginning from the customer’s linear DNA.


The continued expansion of automation capabilities of the BioXp® platform that enable researchers to build DNA and mRNA constructs beginning with linear DNA or plasmid DNA input is expected to further empower researchers to optimize and accelerate their discovery workflows. By providing researchers greater workflow flexibility and automated options to build their DNA or mRNA constructs, they can overcome current bottlenecks created by long synthesis lead times and streamline their design-build-test workflows. Thus, creating efficiencies and accelerating their discovery process.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“The principle of RNAimmune's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. Our research focuses on optimizing the mRNA molecule for delivery, function, and other key characteristics and requires rapid analysis and iteration. The BioXp® System is a key part of our process, enabling us to reduce timelines, eliminate manual steps, and more broadly test and iterate. We expect the new Select DNA Cloning kit to be of great value in our candidate optimization and screening workflows for mRNA vaccines,” said Dong Shen, M.D., Ph.D., Founder and President of RNAimmune.


“The BioXp® Select kit line expands the utility of the system by enabling researchers to begin from existing linear DNA or plasmid DNA. This is our fourth release in 2023, and throughout the year we plan additional releases for DNA and mRNA synthesis beginning from the customer’s sequence, linear DNA, or plasmid DNA, and to expand the BioXp® system to automate NGS Library Preparation thereby providing many customers with a more complete solution for many DNA and mRNA applications,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio. “We believe our BioXp® system can empower researchers to accelerate their breakthrough discoveries. The BioXp® System has the potential to significantly reduce timelines, manual steps, and costs for constructing synthetic DNA and RNA for numerous downstream applications including vaccine development, therapeutics development, diagnostics, precision medicine, and DNA data storage,” continued Todd R. Nelson.